Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag for Right Ventricular Remodeling in PAH (RESTORE)
NCT04435782Phase 4Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 4 trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Started Jul 2021; status: terminated.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04435782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435782.